title: [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
abstract: At present, the direct thrombin inhibitor dabigatran is the only one amongst the new direct anticoagulants which has an effective, specific reversal agent. The novel agent idarucizumab is a humanized, monoclonal antibody fragment binds to dabigatran within minutes thereby offers an opportunity to induce a safe, long-lasting reverse of the anticoagulant effects of dabigatran. The authors describe the first use of idarucizumab in Hungary (23. 05. 2016) in an old female patient with non-valvular paroxysmal atrial fibrillation of high stroke risk-score and renal dysfunction who was taking dabigatran (2 x 110 mg/day) when an acute abdomen developed requiring emergency cholecystectomy. Patient received the antidote (idarucizumab 2 x 2.5 g/50 ml iv.) two hours before the surgical intervention, and she did not have any uncontrollable, life-threatening bleeding during the surgery. The high activated partial thromboplastin time relating to anticoagulative influence before the surgery normalized completely after administration of the antidote. Antagonizing dabigatran with idarucizumab was feasible and safe without any side effects. The patient received dabigatran therapy again after her recovery. Orv. Hetil., 2017, 158(10), 387-392.
authors.affiliation: Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőintézet Szolnok.
authors.forename: Lajos
authors.initials: L
authors.lastname: Driesz
authors.affiliation: Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőintézet Szolnok.
authors.forename: Éva
authors.initials: É
authors.lastname: Barabás
authors.affiliation: Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőintézet Szolnok.
authors.forename: Ildikó
authors.initials: I
authors.lastname: Bodócs
authors.affiliation: Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőintézet Szolnok.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Szántó
authors.affiliation: Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőintézet Szolnok.
authors.forename: György
authors.initials: G
authors.lastname: Herr
authors.affiliation: Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelőintézet Szolnok.
authors.forename: Gábor
authors.initials: G
authors.lastname: Bencsik
authors.affiliation: Boehringer Ingelheim RCV GmbH & Co KG Magyarországi Fióktelepe Budapest.
authors.forename: László
authors.initials: L
authors.lastname: Pál
authors.affiliation: Gottsegen György Országos Kardiológiai Intézet Budapest, Pf. 88, 1450.
authors.forename: József
authors.initials: J
authors.lastname: Borbola
mesh_terms: D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000991:Antithrombins / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D000069604:Dabigatran / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006814:Hungary; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000991:Antithrombins; C000594745:idarucizumab; D000069604:Dabigatran
keywords: antidote; antidótum; dabigatran; direct oral anticoagulants; direkt orális antikoagulánsok; idarucizumab